Physician profile
Patrick M Holly
NPI 1811933583
$14,906.20
in general payments reported to CMS, 2019-2025
58 companies · $3,037 in 2025
The $3,037 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $363 · 2021: $1,495 · 2022: $3,064 · 2023: $2,593 · 2024: $2,939 · 2025: $3,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,544 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,543.72 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,222.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,350.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,343.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,040.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $926.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $782.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Tris Pharma INC | $635.02 | 2019-2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $584.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.07 | 2020-2025 | Jardiance, Stiolto Respimat |
| Sumitomo Pharma America, INC. | $381.44 | 2023-2025 | Gemtesa |
| Amgen INC. | $369.01 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $351.95 | 2019-2025 | Steglatro, Belsomra, Steglujan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.79 | 2020-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $307.96 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.56 | 2020-2025 | Trintellix |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Holly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.